p53 antibody | knockout validation | Cell Signaling 9282
DOI
//dx.doi.org/10.13070/ko.en.7.2036
Date
2017-01-21

This is a knockout-validated antibody summary, based on the publication "Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

p53 antibody | knockout validation | Cell Signaling 9282 figure 1
Figure 1. Western blot of p53 in isogenic HCT-116 (KRAS mutant, p53+/+) and HCT-116 (KRAS mutant, p53−/−) cells. β-actin was used as loading control. From [1].
Antibody information

Rabbit polyclonal

Company: Cell Signaling

Antibody: p53

Catalog number: 9282

Summary: Rabbit polyclonal against full-length human p53 fusion protein. Reacts with human and monkey. Suitable for western blot, immunoprecipitation and ChIP.

Validation Method

Western blot

Sample

HCT-116 (KRAS mutant, p53+/+) and HCT-116 (KRAS mutant, p53−/−) cells. Whole-cell or tumour tissue extracts were prepared by radioimmunoprecipitation assay buffer (150 mM sodium chloride, 50 mM Tris pH 8.0, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 10 mM NaF, 1 mM Na3VO4, 5 mM EDTA, 1 mM EGTA, 5 μg ml−1 leupeptin, 1 μg ml−1 pepstatin A, 1 mM phenylmethylsulfonyl fluoride, and protease and phosphatase inhibitor cocktail (Calbiochem).

Blocking agent

5% bovine serum albumin for 1 h at room temperature.

Primary incubation

1:1,000 dilution in Primary Antibody Dilution Buffer (Beyotime Biotechnology, China) at 4 °C overnight.

Secondary incubation

1:10,000 diluted IRDye 800CW Goat anti-Rabbit IgG (926–32211, LI-COR Biosciences).

Detection

Odyssey Infrared Imaging System (Odyssey, LI-COR).

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, et al. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun. 2016;7:11363 pubmed publisher